Skip to main content
  • About
  • News & Events
  • Careers
  • Contact
  • Subscribe
FR
Canada’s Drug Agency | Drugs, Health Technologies and Systems.
  • Find Reports
    • Programs & Initiatives
      • Appropriate Use
      • Canadian Medical Imaging Inventory
      • Drugs for Rare Diseases
      • Health Systems
      • Health Technology Reviews
      • Horizon Scans
      • Post-Market Drug Evaluation
      • Reimbursement Reviews
      • Scientific Advice
    • Methods
      • Conflict of Interest
      • Methodological Guidelines
      • Program Procedures
    • Tools & Publications
      • Common Acronyms
      • Evidence Bundles
      • HTA Excel Tools
      • Finding the Evidence: Literature Searching Tools in Support of Systematic Reviews
      • Canadian Journal of Health Technologies
    • Provide Input
      • Current Opportunities
      • Instructions
      • Procedures & Templates
    • Engage
      • Sponsor a Reimbursement Review
      • Request Scientific Advice
      • Request an Evidence Review
    • Community Involvement
      • Collaboration and Outreach
      • Patient Groups
      • Pan-Canadian Collaborative
Canada’s Drug Agency | Drugs, Health Technologies and Systems.
FR
  • Find Reports
  • Our Work
    • Programs & Initiatives
      • Advisory Panel: Pan-Canadian Prescription Drug List
      • Appropriate Use
      • Canadian Medical Imaging Inventory
      • Drugs for Rare Diseases
      • Health Systems
      • Health Technology Reviews
      • Horizon Scans
      • Post-Market Drug Evaluation
      • Reimbursement Reviews
      • Scientific Advice
    • Methods
      • Conflict of Interest
      • Methodological Guidelines
      • Program Procedures
    • Tools & Publications
      • Common Acronyms
      • Evidence Bundles
      • HTA Excel Tools
      • Finding the Evidence: Literature Searching Tools in Support of Systematic Reviews
      • Canadian Journal of Health Technologies
  • Get Involved
    • Provide Input
      • Current Opportunities
      • Instructions
      • Procedures & Templates
    • Engage
      • Sponsor a Reimbursement Review
      • Request Scientific Advice
      • Request an Evidence Review
    • Community Involvement
      • Collaboration and Outreach
      • Patient Groups
      • Pan-Canadian Collaborative
  • About
  • News & Events
  • Careers
  • Contact
  • Subscribe

Secukinumab

  • Reimbursement Reviews
    • About Reimbursement Reviews
    • Procedures, Templates, and Fee Schedule
    • Filing an Application
    • Clinician Input Instructions
    • Patient Input Instructions
    • Open Calls
    • Provisional Funding Algorithms
    • Pharmaceutical Review Update
    • Advisory Committees
    • Participating Drug Programs

Details

Last Updated : January 21, 2016

Secukinumab

  • Reimbursement Reviews
    • About Reimbursement Reviews
    • Procedures, Templates, and Fee Schedule
    • Filing an Application
    • Clinician Input Instructions
    • Patient Input Instructions
    • Open Calls
    • Provisional Funding Algorithms
    • Pharmaceutical Review Update
    • Advisory Committees
    • Participating Drug Programs

Details

Last Updated : January 21, 2016

Mifepristone and misoprostol

  • Reimbursement Reviews
    • About Reimbursement Reviews
    • Procedures, Templates, and Fee Schedule
    • Filing an Application
    • Clinician Input Instructions
    • Patient Input Instructions
    • Open Calls
    • Provisional Funding Algorithms
    • Pharmaceutical Review Update
    • Advisory Committees
    • Participating Drug Programs

Details

Last Updated : January 18, 2016

ticagrelor

  • Reimbursement Reviews
    • About Reimbursement Reviews
    • Procedures, Templates, and Fee Schedule
    • Filing an Application
    • Clinician Input Instructions
    • Patient Input Instructions
    • Open Calls
    • Provisional Funding Algorithms
    • Pharmaceutical Review Update
    • Advisory Committees
    • Participating Drug Programs

Details

Last Updated : October 10, 2018

sofosbuvir

  • Reimbursement Reviews
    • About Reimbursement Reviews
    • Procedures, Templates, and Fee Schedule
    • Filing an Application
    • Clinician Input Instructions
    • Patient Input Instructions
    • Open Calls
    • Provisional Funding Algorithms
    • Pharmaceutical Review Update
    • Advisory Committees
    • Participating Drug Programs

Details

Last Updated : January 6, 2016

ledipasvir, sofosbuvir

  • Reimbursement Reviews
    • About Reimbursement Reviews
    • Procedures, Templates, and Fee Schedule
    • Filing an Application
    • Clinician Input Instructions
    • Patient Input Instructions
    • Open Calls
    • Provisional Funding Algorithms
    • Pharmaceutical Review Update
    • Advisory Committees
    • Participating Drug Programs

Details

Last Updated : May 23, 2018

daclatasvir

  • Reimbursement Reviews
    • About Reimbursement Reviews
    • Procedures, Templates, and Fee Schedule
    • Filing an Application
    • Clinician Input Instructions
    • Patient Input Instructions
    • Open Calls
    • Provisional Funding Algorithms
    • Pharmaceutical Review Update
    • Advisory Committees
    • Participating Drug Programs

Details

Last Updated : January 6, 2016

ombitasvir/paritaprevir/ritonavir and dasabuvir

  • Reimbursement Reviews
    • About Reimbursement Reviews
    • Procedures, Templates, and Fee Schedule
    • Filing an Application
    • Clinician Input Instructions
    • Patient Input Instructions
    • Open Calls
    • Provisional Funding Algorithms
    • Pharmaceutical Review Update
    • Advisory Committees
    • Participating Drug Programs

Details

Last Updated : January 6, 2016

Emtricitabine /tenofovir alafenamide

  • Reimbursement Reviews
    • About Reimbursement Reviews
    • Procedures, Templates, and Fee Schedule
    • Filing an Application
    • Clinician Input Instructions
    • Patient Input Instructions
    • Open Calls
    • Provisional Funding Algorithms
    • Pharmaceutical Review Update
    • Advisory Committees
    • Participating Drug Programs

Details

Last Updated : October 9, 2018

Sapropterin dihydrochloride

  • Reimbursement Reviews
    • About Reimbursement Reviews
    • Procedures, Templates, and Fee Schedule
    • Filing an Application
    • Clinician Input Instructions
    • Patient Input Instructions
    • Open Calls
    • Provisional Funding Algorithms
    • Pharmaceutical Review Update
    • Advisory Committees
    • Participating Drug Programs

Details

Last Updated : January 4, 2016

Pagination

  • Previous page ‹‹
  • Page 105
  • Next page ››

Canada’s Drug Agency is a pan-Canadian health organization, created and funded by Canada’s federal, provincial, and territorial governments.

We provide Canada’s health system leaders with independent evidence and advice so they can make informed drug, health technology, and health system decisions, and we collaborate with national and international partners to enhance our collective impact. 

  • Reports
  • Contact
  • Careers
  • Help

Stay up to date on the latest from Canada’s Drug Agency by subscribing to our newsletter.

Already subscribed? Update your preferences.

  • visit us on facebook
  • visit us on linkedin
  • visit us on youtube
  • visit us on instagram

© 2025 Canadian Agency for Drugs and Technologies in Health

  • Privacy Policy
  • Terms of Use
  • Accessibility
  • Request for Archived Report
Back to Top